Pharmaceuticals, Biotechnology and Life Sciences
The U.S. Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) for Allergan’s Avycaz (ceftazidime and avibactam) for priority review.
Allergan has reached a settlement regarding its litigation with Famy Care Limited relating to certain Allergan’s United States Patent covering Restasis (Cyclosporine Ophthalmic Emulsion) 0.05%.
Allergan’s wholly-owned subsidiary, Allergan Sales LLC has acquired Keller Medical, a privately held medical device company and developer of the Keller Funnel.
Emmy and Tony award-winning actress and singer, Kristin Chenoweth will kick off Allergan’s “Less Red, More You” campaign at an exclusive event in New York City.
Allergan announced that it expects to commence an offering of euro-denominated senior unsecured notes in multiple tranches in the coming weeks.
Allergan will collaborate with Target PharmaSolutions on its five-year longitudinal observational study that looks at patients with nonalcoholic fatty liver disease (NAFLD) or nonalcoholic steatohepatitis (NASH).
Novartis and Allergan have joined forces to conduct a Phase IIb study to test combination of a Novartis FXR agonist and Allergan’s cenicriviroc (CVC) for the treatment of non-alcoholic steatohepatitis (NASH).
Allergan has received approval from the U.S. Food and Drug Administration (FDA) to market JUVÉDERM VOLLURETM XC, for correction of moderate to severe facial wrinkles and folds, such as nasolabial folds, in adults over the age of 21.
U.S. Food and Drug Administration (FDA) has accepted Allergan’s supplemental New Drug Application (sNDA) for VRAYLAR (cariprazine), seeking the addition of new clinical data evaluating VRAYLAR for the maintenance of efficacy in adults with schizophrenia to the current product label.
Former Allergan boss David Pyott signed as special advisor to Sienna Biopharmaceuticals, a privately held, clinical-stage medical dermatology and aesthetics company.